



## Revive Therapeutics Files Business Acquisition Report

TORONTO, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“**Revive**” or the “**Company**”) (CSE:RVV) (USA: RVVTF), announces that it has filed a Form 51-102F4 *Business Acquisition Report* (BAR) pursuant to National Instrument 51-102 *Continuous Disclosure Obligations* in connection with its acquisition of Psilocin Pharma Corp. on March 5, 2020. The BAR has been filed as a result of a review conducted by staff at the Ontario Securities Commission in connection with the Company’s recently filed preliminary short form prospectus dated January 26, 2021.

**For more information, please contact:**

Michael Frank  
Chief Executive Officer  
Revive Therapeutics Ltd.  
Tel: 1 888 901 0036  
Email: [mfrank@revivetherapeutics.com](mailto:mfrank@revivetherapeutics.com)  
Website: [www.revivetherapeutics.com](http://www.revivetherapeutics.com)